A thourough review of all conference presentations (oral and poster presentations) was performed to retrieve the key outcomes of the conference.
Introduction
HIV and viral hepatitis continue to pose major challenges to public health throughout the World Health Organization (WHO) European Region, which includes 53 Member States. Despite effective treatments, cost-effective testing strategies and evidence-based prevention strategies, the number of new diagnoses continues to increase in some parts of the region and in some population groups. Late presentation remains at approximately 50% for HIV and possibly higher for viral hepatitis, and although reliable data is lacking, linkage to and retention in care for both infections are inadequate, resulting in avoidable morbidity, mortality and onward transmission [1] .
Beginning with its inaugural conference in Brussels in 2007, the HIV in Europe initiative has organised a series of biennial conferences dedicated to optimal testing and earlier care [2] [3] [4] [5] . The HepHIV 2017 Conference in Malta was the second of these conferences to address HIV and viral hepatitis in tandem.
There had been several positive developments since the first HepHIV conference took place in Barcelona in 2014, providing further evidence of the benefits of earlier diagnosis, a key objective of the HIV in Europe initiative. Results from the START Study, which concluded in 2015, showed that patients diagnosed with HIV should initiate treatment as early as possible [6] . Additional evidence demonstrated the effectiveness of "treatment as prevention" in reducing the risk of onward transmission [6, 7] . WHO issued new consolidated guidelines on HIV testing services, including guidance on self-testing and partner notification [8, 9] . Both provider-initiated and community-based testing became more widespread. The emergence of new treatments for hepatitis C made elimination as a public health threat a genuine possibility, though that would require revision of existing policies and the development of new testing strategies to identify and treat the very large undiagnosed population [10] .
The Barcelona conference had shown the benefits of European collaboration between the fields of HIV and viral hepatitis, and HIV in Europe decided to continue and strengthen the dialogue in the next conference.
The HepHIV conferences have given researchers, providers and programme implementers a forum to share experiences and present research on the topics of testing and linkage to care -topics that international HIV and hepatitis conferences do not often address. The large number of abstracts submitted for the last three HIV in Europe conferences -around a hundred for each conference -testifies to the level of activity on these issues, as well as the need for a conference dedicated to them.
HepHIV 2017 was held from 31 January to 2 February 2017 in Malta, to coincide with the Maltese presidency of the European Union (EU). More than 250 people attended the three-day conference, including community activists, clinicians, policymakers and public health officials. Among the bodies represented were the Maltese Ministry of Health, the EU, the European Centre for Disease Prevention and Control (ECDC), WHO, the European AIDS Treatment Group (EATG) and the European Liver Patients Association (ELPA). This supplement presents the results of some of the most important research and implementation efforts that were presented at the Malta conference.
Conference focus
As reflected in the contributions to this supplement, the parallel sessions at the conference focused on testing strategies for key populations, programme monitoring, and testing and linkage to care in health care and community settings. The programme also featured a special session on HIV pre-exposure prophylaxis (PrEP) and its effect on testing, and two roundtable discussions, on unequal access to hepatitis C treatment and on the ways that stigma and criminalization discourage testing [11] .
Much of the material that was presented came from two projects that have been co-funded by the EU: Optimising Testing and Linkage to Care for HIV Across Europe (OptTEST) and the European HIV Early Diagnosis and Treatment Project (Euro HIV EDAT) [12, 13] . Both projects have generated a good deal of new evidence, some of which is featured in this supplement.
Late presentation
In 2009, two working groups established a consensus definition of late presentation for HIV treatment and care [14] . Since then, the definition has served as an Table 1 HepHIV 2017 -Call for Action All of us -people living with HIV and with viral hepatitis, civil society representatives, health professionals, public health officers and decisionmakers, policymakers, representatives from European and national institutions, and researchers -need to keep collaborating closely to decrease the number of people initiating HIV and HCV treatment late, in order to improve long-term health outcomes and reduce onward transmission. The year 2016 saw the adoption of the very first global health sector strategy on viral hepatitis, a turning point in efforts to fight the disease, and of a corresponding strategy on HIV. The participants in the HepHIV 2017 Conference call on all stakeholders to work together to achieve the targets and goals in these strategies, and to exceed them when possible, by implementing the following actions.
(1) Improve surveillance of viral hepatitis and the late presentation of viral hepatitis, and support ECDC efforts in this area. (2) Improve the monitoring and evaluation of programmes and services with respect to testing and linkage to care for HIV, viral hepatitis and sexually transmitted infections, (STIs), and promote the sharing of their best practices. (3) Improve HIV and viral hepatitis testing strategies:
• tailor HIV and viral hepatitis screening strategies to each country's epidemics, including at the subnational level;
• expand and support community-based testing for HIV and viral hepatitis by trained laypeople;
• make self-testing and self-sampling an integral part of the testing toolkit;
• educate general practitioners and other health care providers about testing strategies, including the importance of prompt referral to specialist care, and facilitate the implementation of indicator condition-guided testing;
• develop new, affordable testing diagnostics, and utilize them; and
• increase testing frequency and testing at early stages of infection when cost-effective, particularly in high-risk populations. (4) Create synergies between efforts to tackle communicable and noncommunicable diseases by encouraging partnerships and collaborations, including tandem testing, among people working with HIV, viral hepatitis, TB and STIs. (5) Advocate for stronger political leadership in implementing evidence-based public health interventions by the EU and its member states, as well as by other governments and international agencies in the WHO European Region. (6) Remove all restrictions on direct-acting antiviral (DAA) therapy for hepatitis C, and make it immediately available for all people living with active hepatitis C. (7) Drawing on the support and involvement of all stakeholders, urge governments to negotiate effectively to ensure universal access to DAA therapy. (8) Make pre-exposure prophylaxis (PrEP) available to everyone who needs it, as an integral part of HIV prevention. (9) Scale up efforts to combat stigma and discrimination by:
• telling the 21 st century HIV and viral hepatitis story -that diagnosis and treatment can ensure a long and healthy life and stop onward transmission;
• normalizing and expanding HIV and viral hepatitis testing;
• promoting national and regional monitoring of stigma, discrimination and unjust criminalization; and
• developing more effective interventions to combat stigma, discrimination and unjust criminalization. (10) Challenge policies that prevent undocumented migrants from accessing HIV and viral hepatitis prevention, testing, treatment and care.
invaluable tool for evaluating the effectiveness of HIV testing efforts [15] . In 2014, another working group took on the task of formulating a comparable definition of late presentation for viral hepatitis. Published in 2017 [16] , the resulting definition allows researchers to evaluate changes in the liver disease burden over time, as well as facilitating the improved monitoring of hepatitis testing and referral services. However, as highlighted during HepHIV 2017, the effective use of the definition requires better collection and reporting of data on people living with viral hepatitis (Table 1) .
Mixing HIV testing strategies to reach the undiagnosed
As a variety of presentations made clear, ending HIV transmission in the European Region will require the expansion of testing initiatives and linkage to care in a wide range of settings. In the past three years, OptTEST and Euro HIV EDAT have focused on improving testing and linkage to care in health care settings and community settings, respectively. Unfortunately, findings from the latest monitoring data [17] indicate that only 11 of the 31 countries in the European Economic Area permit trained non-medical staff to provide HIV testing. While self-testing and home sampling have both proven to be successful in reaching people who normally do not get tested for HIV, governments need to assume a proactive role in removing legal and regulatory barriers and facilitating implementation of national and European policies. Unfortunately, stigma and discrimination remain major reasons for low HIV testing uptake in the region, particularly among key populations. Identifying and describing these phenomena where they occur is crucial to improve access to testing [18, 19] .
One strategy that can help reduce stigma and discrimination and improve HIV testing uptake is indicator condition-guided testing. Because indicator conditions are more likely to occur in the presence of HIV, they provide a health care professional with a clinical reason for testing that is not based on an evaluation of behavioural risk. As part of OptTEST, clinics and hospitals in the EU and in three non-EU countries (Belarus, Georgia and Ukraine) have implemented this strategy, testing a number of tools to better equip health care workers to offer HIV testing. Yet although this strategy has been proven to be cost-effective and is included in many HIV testing guidelines [20] , it is rarely effectively implemented [21] . One important way to promote this strategy is to recommend HIV testing in the speciality guidelines for the various indicator conditions -something that most of the relevant guidelines do not yet do [22] .
In general, the support and commitment of national governments is key to improving testing strategies. Yet in order to develop an effective national testing strategy, it is important to know which testing frequencies are costeffective for which groups. Based on an analysis of the HIV situation in Estonia, France and Spain, OptTEST has developed cost-effective recommendations for testing frequency in different population groups, depending on the national GDP and type of epidemic [23] . These recommendations have the potential to have a significant impact on testing policies, and they should be further developed to ensure that they apply to other countries in the region.
Improved testing approaches also need to be accompanied by better linkage to care. Unfortunately, results presented at the conference showed that in many European countries, the data available on linkage to care remain inadequate. Moreover, a literature review demonstrated that while many studies have examined linkage to care, the many different national definitions for linkage to care make comparisons between countries difficult [24] . In addition, the implementation of new testing approaches, such as self-testing and home sampling, requires the establishment of corresponding procedures for confirmatory testing and linkage to care.
To respond effectively to any epidemic, collaboration is critical. Not only among experts from different fields, but also among different stakeholders. In addressing HIV and viral hepatitis, that means involving everyone from community groups to governments to the diagnostic companies that develop new testing technologies. The HepHIV conferences have showcased high levels of engagement and willingness to collaborate across different specialities and settings. As announced during the conference, the European Commission is pursuing further integration of disease areas, most notably through a newly approved joint action to integrate prevention, testing and linkageto-care strategies in HIV, viral hepatitis, tuberculosis and sexually transmitted infections, a project known as INTE-GRATE. Twenty-nine partners from 15 countries will be identifying, adapting and utilising tools, materials and processes to improve testing and linkage to care for these infections. The HepHIV Conference Organizing Committee and HIV in Europe initiative also welcomed the news that the ECDC is developing the first European testing guide to combine testing for HIV and viral hepatitis.
From policy to practice
Implementation often lags behind policy and guideline improvements, and that is certainly true of HIV and hepatitis testing. A good example is indicator condition-guided testing, as described above. Similarly, policy lags behind scientific and technological advances. As was also noted above, the advent of new hepatitis C drugs has increased the pressure on governments to develop policies and strategies to expand testing and treat everyone living with hepatitis C. While governments will need to negotiate in order to afford the new drugs, they will also have to be more effective in targeting the most vulnerable, such as people who inject drugs and people in prison, and to scale up community-based hepatitis C testing. That in turn will increase treatment uptake and ultimately reduce the disease burden. The development of expensive new drugs that can cure hepatitis C has placed significant pressure on national governments. During the roundtable on hepatitis C, there was agreement on the urgent need for national governments to negotiate lower prices in order to ensure access for all people living with hepatitis C. These new and highly effective drugs have also made it increasingly important to improve testing, surveillance and access to care.
Finally, an integrated approach is also critical for policy and practice. New HIV prevention strategies such as PrEP have made hepatitis C screening more urgent, based on accumulating evidence of a higher risk of hepatitis C transmission among men who have sex with men (MSM) [25] . This point needs to be emphasized, particularly since recent data from the ECDC show very limited screening of hepatitis C in the European Region [26] .
Conclusions
The European Region is home to a wealth of knowledge about HIV and viral hepatitis, knowledge that needs to be disseminated more widely and acted upon in order to optimize testing and linkage to care for these viruses. The number and variety of stakeholders from across the region who took part in HepHIV 2017 created a vibrant platform for the exchange of experiences and findings in the fields of HIV and viral hepatitis, reinforcing existing collaborations and forging new ones. By drawing on the engagement and knowledge of these participants, the HIV in Europe initiative and its partners are developing the integrated approach to earlier testing and linkage to care that the region needs. 
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